Omega-3 polyunsaturated fatty acid (w-3 PUFA) therapy shows promise in primary and secondary prevention of cardiovascular diseases.
I t has been more than 7 years since the American Heart Association (AHA) endorsed the use of omega-3 polyunsaturated fatty acid (w-3 PUFA), at a dose of approximately I g/day of combined eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), as either fatty fish or fish oil supplements (in capsules or liquid form), for individuals with documented coronary heart disease (Kris-Etherton, Harris, & Appel, 2002) .
The use of w-3 PUFA therapy continues to show promise in primary, and particularly in secondary, prevention of cardiovascular diseases. A recent review of the literature (Lavie, Milani, Mehra, & Ventura, 2009) suggests that w-3 PUFA provides benefit to healthy individuals as well as those with heart disease including atrial fibrillation, post-myocardial infarction, and heart failure.
In reviewing the evidence from large randomized, controlled trials and retrospective epidemiologic studies demonstrating the effects of the benefits of w-3 PUFA, specifically EPA in primary and secondary cardiovascular disease prevention, Lavie et al. (2009) have found evidence that w-3 PUFA prevents and treats many aspects of cardiovascular disease. The review did not focus on alphalinolenic acid (ALA), the plant-based precursor of EPA; however, the avail- The author discloses that she has no significant financial interests in any product or class of products discussed directly or indirectly in this activity, including research support. doi: 10.3928/08910 162-20091027-05 480 able evidence was much weaker for ALA than for EPA and DHA.
There is evidence of benefit in atherosclerosis and in a wide range of arrhythmias, with the most significant effect and potential benefit seen in atrial fibrillation. However, Lavie et al. (2009) suggest that more studies are needed to explore the effects of various doses of w-3 PUFAs on the primary and secondary reduction of atrial fibrillation.
Although there may not be additional short-term benefit of w-3 PUFAs for low-risk individuals already receiving optimal therapy for congestive heart failure, large randomized trials have demonstrated that in primary and secondary prevention settings, w-3 PUFAs lower total mortality, sudden death, and cardiovascular mortality by as much as 30% (Lavie et al., 2009) .
The potential benefits of w-3 PUFAs extend to the prevention and treatment of heart failure, reducing total mortality among individuals with heart failure by 8% (Lavie et al., 2009) .
The current AHA dietary guidelines recommend healthy individuals with no known coronary heart disease consume at least 500 mg/day of EPAlDHA (about two fatty-fish meals per week). Those with known coronary heart disease or those with heart failure should consume at least 800 to 1,000 mg/day (Kris-Etherton et al., 2002) . Lavie et al. (2009) suggest that the coronary heart disease recommendations also be extended to individuals with heart failure.
Unlike in swordfish, albacore tuna, tilefish, and shark, methyl mercury contaminants are rare in fish oil supplements. Fish that are most likely to be contaminated with methyl mercury are not commonly used in the manufacture of supplements. Omega-3 PUFAs are usually formulated from small pelagic fish. Additionally, mercury is tightly bound to fish proteins, so it is therefore present in the muscle of the fish but not in the oil, further reducing the risk of commercially available fish oil capsules. Thus, similar to dietary consumption of the majority of fish and seafood species, significant exposure to contaminants from fish oil is not a clinical concern (Mozaffarian & Rimm, 2006) .
The most common side effects of fish oil supplements are gastrointestinal disturbances such as nausea, which occur in approximately 4% of individuals at doses below 3 g/day and in approximately 20% of individuals at doses of 4 g/day or higher (Wang et al., 2006) . The "fishy" taste accompanying eructation that may occur can be minimized by taking the supplement with meals, changing formulation, or freezing the capsule.
